|
全民健康保險藥品給付規定 / 健保碼及健保價 |
|
See related Keppra[優閒] information |
|
|
|
製造商 |
GlaxoSmithKline |
|
代理/經銷商 |
GlaxoSmithKline |
|
成份 |
Levetiracetam |
|
適應症 |
Monotherapy in the treatment of partial onset seizures with or without secondary generalization in patients from 16 years with epilepsy. As adjunctive therapy in the treatment of partial onset seizures with or without secondary generalization in adults & children ≥ 4 years with epilepsy. Adjunctive therapy in the treatment of myoclonic seizures in adults & adolescents from 12 years with Juvenile Myoclonic Epilepsy. Adjunctive therapy for patients ≥ 16 years with Primary Generalized Tonic, Clonic Seizure (PGTCS). |
|
用量 |
Monotherapy Adult & adolescent from 16 years 250 mg bid which should be increased to 500 mg bid after 2 weeks. May further increase by 250 mg bid every 2 weeks. Max: 1500 mg bid. Add-on therapy Adult (≥ 18 years) & adolescent (12-17 years) ≥ 50 kg Initially 500 mg bid. May increase up to 1500 mg bid. Dose titration can be made in steps of 500 mg bid increases & decreases every 2-4 weeks. Children 4-11 years & adolescents (12-17 years) < 50 kg Initially 10 mg/kg bid. May increase up to 30 mg/kg bid. Dose changes should not exceed increases or decreases of 10 mg/kg bid every 2 weeks. Max: 60 mg/kg daily. From 50 kg Initially 500 mg bid, max: 1500 mg bid; 25 kg Initially 250 mg bid, max: 750 mg bid; 20 kg Initially 200 mg bid, max: 600 mg bid; 15 kg Initially 150 mg bid, max: 450 mg bid. Children < 20 kg Preferably start treatment with oral soln. |
|
用法 |
May be taken with or without food |
|
美國食品藥物管理局之懷孕等級 |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
注意事項 |
Hepatic or renal impairment; pregnancy & lactation. May impair ability to drive or operate machinery. Avoid abrupt withdrawal. Symptoms of depression &/or suicidal ideation. Patients with rare hereditary problems of fructose intolerance should not take oral soln. |
|
不良反應 |
Asthenia/fatigue; somnolence, amnesia, ataxia, convulsion, dizziness, headache, hyperkinesia, tremor, balance disorder, attention disturbance, memory impairment; agitation, depression, emotional lability/mood swings, hostility/aggression, insomnia, nervousness/irritability, personality disorders, thinking abnormal; abdominal pain, diarrhea, dyspepsia, nausea, vomiting; anorexia, weight increase; vertigo; diplopia, vision blurred; myalgia; accidental injury; infection, nasopharyngitis; cough increased; rash, eczema, pruritus; thrombocytopenia.
View ADR Monitoring Website[參閱藥物不良反應監測表格] |
|
本商品之市售規格 |
|
劑型 |
包裝 |
圖片 |
|
Keppra 膜衣錠 |
|
Keppra 250 mg |
|
Keppra 500 mg x 60's |
 |
|
|
Keppra 內服液劑 |
|
Keppra 100 mg/1 mL x 150 mL |
|
Keppra 100 mg/1 mL x 300 mL |
|
|
|
Manufacturer: |
GlaxoSmithKline |
|
Distributor: |
GlaxoSmithKline |
|
|
|
|
|
